Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

It’s the same question sickle cell patients nationwide have been asking since the ... where technicians will use a ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science Foundation’s Faculty Early Career Development Program (CAREER) for ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex could receive roughly $100 million in top-line sales. Unfortunately, CRISPR ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

CRISPR and Vertex's two phase 1/2 studies in thalassaemia and SCD – called CLIMB-111 and CLIMB-211, respectively – have now recruited 19 patients. They are due to enrol 45 apiece, and are ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

It’s the same question sickle cell patients nationwide have been asking ... where technicians will use a gene-editing tool called CRISPR to modify a gene in the stem cells so they produce ...